Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lanreotide 120 mg Effectiveness in Subjects With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice

NCT03947762 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03947762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03947762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lanreotide 120 mg Effectiveness in Subjects With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice
Lead sponsor
Ipsen
Phase
Observational
Overall status
Terminated
Start date
July 3, 2019
Completion date
April 30, 2021
Enrollment
54 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine tumor